Strota/ Newsroom/ 2026-07-20

APLLTD (APLLTD): Regulatory Approval

Strota Newsroom · session of 2026-07-20 · 18 Jul 20:35 · APLLTD stock page →

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "Alembic…

Alembic Pharmaceuticals has informed the Exchange that its partner NATCO Pharma Limited received USFDA Tentative Approval for Olaparib Tablets in 100 mg and 150 mg strengths, according to a press release dated July 18, 2026. The filing, made on July 20, 2026, marks the second regulatory approval event for the company in under a month—Alembic had earlier received USFDA Final Approval for Dapsone Gel, 5% on June 26, 2026.

Events like this—USFDA regulatory approvals for Indian pharmaceutical companies—have historically shown positive short-term price reactions in the days following the announcement, based on Strota's base rate analysis across comparable filings. This pattern reflects market pricing of incremental revenue visibility from the US generics market, though the base rate describes past behaviour across many stocks and does not predict any specific outcome for APLLTD.

At current levels, Alembic Pharmaceuticals trades at a price-to-earnings ratio of 24.04 and a price-to-book ratio of 2.86, with a market capitalisation of ₹16,218 crore. The company reports a return on equity of 12.4% and a dividend yield of 1.45%, with earnings per share at ₹34.32. The Nifty 50 has moved 1.09% over the relevant period.

The filing establishes that a partner has secured tentative approval for a oncology reference-listed drug, not final approval or immediate commercial launch. What the data does not establish is the revenue share arrangement between Alembic and NATCO, the timing of market entry, or the competitive intensity of the Olaparib generic landscape in the United States.

The catalyst

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 18, 2026, titled "Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg". (filing · NSE)

What the data shows after this event

Strota has not yet measured a reliable next-session base rate for Regulatory Approval events on enough history.

APLLTD right now

P/E 24.04. Full APLLTD analysis →

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.